The Family Heart Foundation announced the results of the largest study to date involving individuals with cardiovascular disease and a confirmed measurement of lipoprotein(a) [Lp(a)]. The findings,...
READ MORE
A new head-to-head clinical trial comparing tirzepatide and semaglutide for weight loss in people with obesity but without diabetes demonstrates that tirzepatide led to significantly greater weight...
READ MORE
Accurate imaging of coronary artery disease (CAD) plays a vital role in guiding clinical decisions, particularly in patients with high coronary calcium scores. While conventional coronary CT angiog
READ MORE
A new expert consensus document jointly released by the Society for Cardiovascular Angiography and Interventions (SCAI) and the Society of Cardiovascular Computed Tomography (SCCT) offers a detailed...
READ MORE
Approximately 6.7 million adults in the U.S. are currently living with heart failure, a number projected to exceed 8 million by 2030. A recent study published in Circulation: Heart Fail
READ MORE
New research published in the New England Journal of Medicine reveals that semaglutide effectively treats liver disease in nearly two-thirds of patients, offering new hope for those with metabolic...
READ MORE
Cardiovascular disease (CVD) is a major cause of death in the U.S., and risk factors like high BMI, blood pressure, and cholesterol in early childhood are linked to CVD-related mortality in adulthood
READ MORE
For nearly 60 years, blood cholesterol levels have been the primary tool for identifying individuals at high risk of cardiovascular disease (CVD). However, a new large-scale study led by researcher
READ MORE
Over the past 20 years, the average rate of obesity among U.S. adults has increased by nearly 30%. However, the prevalence of the most extreme forms of obesity—defined as having a body mass index...
READ MORE
Despite the availability of effective treatments, accessible strategies for heart failure (HF) risk stratification remain limited. Current clinical risk scores (e.g., PCP-HF, PREVENT, Health ABC)...
READ MORE
![Medtronic Secures CE Mark for Innovative Pulmonary Valve Replacement System for Congenital Heart Disease"](https://res.cloudinary.com/healthmanagement-org/image/upload/c_thumb,f_auto,fl_lossy,h_100,q_90,w_100/v1736278991/cw/00129025_cw_image_wi_87dba3e3d5217851f249d0509c004718.webp "Medtronic Secures CE Mark for Innovative Pulmonary Valve Replacement System for Congenital Heart Disease"")
